US8999382B2 - Drug delivery system for administration of poorly water soluble pharmaceutically active substances - Google Patents

Drug delivery system for administration of poorly water soluble pharmaceutically active substances Download PDF

Info

Publication number
US8999382B2
US8999382B2 US12/809,252 US80925208A US8999382B2 US 8999382 B2 US8999382 B2 US 8999382B2 US 80925208 A US80925208 A US 80925208A US 8999382 B2 US8999382 B2 US 8999382B2
Authority
US
United States
Prior art keywords
methyl ester
sodium salt
cysteic acid
retinoyl cysteic
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/809,252
Other languages
English (en)
Other versions
US20110014281A1 (en
Inventor
Julian Aleksov
Igor Lokot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardenia Investments Ltd
Vivesto AB
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8999382(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Assigned to ARDENIA INVESTMENTS, LTD. reassignment ARDENIA INVESTMENTS, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALEKSOV, JULIAN, LOKOT, IGOR
Publication of US20110014281A1 publication Critical patent/US20110014281A1/en
Application granted granted Critical
Publication of US8999382B2 publication Critical patent/US8999382B2/en
Assigned to OASMIA PHARMACEUTICAL AB reassignment OASMIA PHARMACEUTICAL AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARDENIA INVESTMENTS, LTD.
Priority to US16/899,848 priority Critical patent/USRE49741E1/en
Priority to US17/177,550 priority patent/USRE49742E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substances, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system.
  • the invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles.
  • the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.
  • Industrially useful water insoluble or poorly water soluble substances include water insoluble or poorly water soluble biologically useful compounds, imaging agents, pharmaceutically useful compounds and in particular water insoluble and poorly water soluble drugs for human and veterinary medicine.
  • water-insoluble or poorly water soluble substances for use in the present invention.
  • examples include antipyretics, anti-inflammatories, analgesics, ataractics, sedatives, antitumor agents, antimicrobials, antibiotics, antilipemics, antitussives/expectorants, muscle relaxants, antiepileptics, antiulcers, antidepressants, antiallergics, cardiotonics, antiarrhythmics, vasodilators, hypotensors/diuretics, diabetes therapeutics, tuberculostatics, antirheumatics, steroids, narcotic antagonists, hormones, fat-soluble vitamins, anticoagulants, ischemic disease therapeutics, immune disease therapeutics, Alzheimer's disease therapeutics, osteoporosis therapeutics, angiopoiesis therapeutics, retinosis therapeutics, retinal vein occlusion therapeutics, senile disciform macular degeneration, cerebrovascular spasm therapeutics,
  • Paclitaxel and docetaxel belong to the taxane class of anticancer drugs because they or their precursors are produced by the plants of the genus Taxus (yews). Paclitaxel is still produced by isolation from natural sources while docetaxel, a semi-synthetic analogue of paclitaxel, is synthesized from 10-deacetyl baccatin. Paclitaxel differs from docetaxel by an acetylated hydroxyl function at position 10 and a benzoyl moiety instead of tert-butyl on the phenylpropionate side chain.
  • taxanes The mechanism of action of taxanes is based on their ability to bind to the ⁇ subunit of tubulin which interferes with the depolymerization of microtubules, thereby damaging dividing cells. This specificity of action is widely used in oncology to treat different solid tumors, especially ovarian, lung, breast, bladder, head and neck cancer.
  • Paclitaxel and docetaxel have poor oral bioavailability and therefore intravenous (i.v.) infusion is the only way of administration. Scarce water solubility also makes it impossible to use aqueous solutions of these taxanes. Several delivery vehicles have been applied to solve this problem.
  • TAXOL® is based on the ability of CREMOPHOR® EL, a polyethoxylated castor oil, to dissolve paclitaxel in the weight-to-weight (w/w) ratio 87:1. It is chronologically the first commercial taxane formulation which has opened the era of taxane use in oncology. However it was later found that CREMOPHOR® is the cause of hypersensitivity reactions during TAXOL® infusion and for minimization of the incidence and severity of these reactions a premedication with histamine blockers and glucocorticoids as well as continuous infusion schedules became standard practice.
  • Polysorbate 80 (known under the trademark TWEEN® 80), a derivative of polyethoxylated sorbitol and oleic acid, plays the role of vehicle. In this case the w/w ratio is 24:1. Like CREMOPHOR® EL, Polysorbate 80 is a non-ionic detergent build of polyethoxy chains and can also induce hypersensitivity reactions.
  • ABRAXANE® a third delivery system, consists of paclitaxel nanoparticles stabilized by human serum albumin in the w/w ratio 9:1 with the mean diameter of nanoparticles being 130 nm.
  • the ABRAXANE® formulation is less potent than TAXOL® because ABRAXANE® nanoparticles like other particles with the size more than 100 nm are a substrate for reticuloendothelial system.
  • Another disadvantage of this drug delivery vehicle is that human serum albumin isolated from donor blood is used, which always carries a small but definite risk of transmission of viral diseases.
  • paclitaxel and docetaxel can be dissolved in aqueous solutions of water-soluble derivatives of retinoic acid acting as anionic surfactants.
  • Ixabepilone (epothilone B analog) is very similar to taxanes in terms of mode of action and solubility in aqueous solutions. It is indicated for the treatment of metastatic or locally advanced breast cancer. Formulation of ixabepilone for IV administration, Ixempra, developed by BMS, like Taxol, is based on cremophor EL and therefore a premedication and prolonged infusion for the reducing of hypersensitivity reactions is required.
  • Etoposide analog of toxin podophyllotoxin, is topoisomerase II inhibitor and is used for treatment of Ewing's sarcoma, lung cancer, testicular cancer, lymphoma and non-lymphocytic leukemia.
  • Etoposide formulations for IV administration are based on PEG-derivatives such as Polysorbate 80 (TWEEN 80) or Macrogol 300 in order to solubilize the scarce water soluble active pharmaceutical ingredient.
  • Retinoids comprise a family of polyisoprenoids which includes vitamin A (retinol) and its natural (retinoic acid) and synthetic analogs (fenretinide, etretinate, tazarotene, bexarotene, adapalene). These compounds show a broad spectrum of biological activity including participation in control of cell proliferation, cell differentiation and embryonic development which enables to use retinoids as antineoplastic agents for treatment of different types of cancer such as leukemia, lymphoma, Kaposi's sarcoma, lung cancer and breast cancer. These compounds are also used for treatment of different skin disease like psoriasis, acne, and sun damaged skin. Retinoids are usually highly lipophilic compounds and their usage in form of aqueous solution demands application of some delivery system. However so far there are no any commercially developed water-soluble formulations of retinoids and they are available exclusively for oral administration.
  • Ciclosporin, sirolimus, tacrolimus, and everolimus are immunosuppressants which are scarcely water soluble. Bioavailability of the drugs at oral administration is only about 20%. Commercially available formulations of these immunosuppressants are based solely on the use of polyoxyethylated castor oil, which causes hypersensitivity reactions when intravenously administered.
  • Ciclosporin, cyclosporine, or cyclosporin is an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of a patient's immune system and so the risk of organ rejection. It has been studied in transplants of skin, heart, kidney, liver, lung, pancreas, bone marrow and small intestine. Initially isolated from a Norwegian soil sample, Ciclosporin A, the main form of the drug, is a cyclic nonribosomal peptide of 11 amino acids (an undecapeptide) produced by the fungus Tolypocladium inflatum Gams, and contains D-amino acids, which are rarely encountered in nature.
  • a particle becomes “visible” to the reticulo-endothelial system, a part of the immune system consisting of the phagocytic cells located in reticular connective tissue of lymph nodes, liver and spleen.
  • the extent of reticulo-endothelial system clearance increases with the size of the particles, significantly reducing the total amount of the drug in the blood flow.
  • Nanoparticles have been found very useful in this regard. Solid tumors differ pathoanatomically from healthy tissues by an extensive angiogenesis, as well as a hyperpermeable and defective vasculature architecture. In other words the size of the tumour capillaries is larger, making it potentially possible to significantly increase the passive transport of nanoparticles loaded with cytotoxic cargo to the tumour in comparison to a healthy endothelium.
  • US 2004048923 describes a group of retinoids including among numerous others the sodium salt of N-(all-trans-retinoyl)-L-cysteic acid methyl ester and the sodium salt of N-(13-cis-retinoyl)-L-cysteic acid methyl ester. It is stated that the substances make it possible to manufacture new micelle formulations of poorly soluble pharmaceutical compounds like paclitaxel and docetaxel.
  • WO 02092600 relates to a method for preparing a water-soluble formulation of paclitaxel, comprising the steps of dissolving paclitaxel in a first solvent, dissolving a compound chosen among N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, and N-(13-cis-Retinoyl)-L-cysteinesulfinic acid in a second solvent, mixing the aliquots of the resulting solutions of paclitaxel and the said compound in a desired molar ratio, and evaporating the resulting mixture to
  • One object of the present invention is to provide such a drug delivery system.
  • one aspect of the invention relates to a drug delivery system for administration of at least one pharmaceutically active substance having a solubility per se in water of less than about 100 ⁇ g/ml, said substance being in particulate form with an effective average particle size of less than about 100 nm, wherein the substance particles are essentially amorphous; the substance particles are entrapped in nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof; and the weight-to-weight ratio of said sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to said substance is in the range from 0.5:1 to 20:1.
  • FIG. 1 shows the dependence of the particle size on the w/w ratio of sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid to paclitaxel at different paclitaxel concentrations in an aqueous solution of sodium chloride at a concentration of 9 mg/ml.
  • FIG. 2 shows the dependence of the size of particles formed by sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid and docetaxel (w/w ratio 1:1) on the concentration of sodium chloride at different docetaxel concentrations.
  • FIG. 3 shows the dependence of the size of particles formed by sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid and paclitaxel (w/w ratio of paclitaxel:methyl ester of N-all-trans-retinoyl cysteic acid is 1:2) on the concentration of calcium chloride in an aqueous solution of sodium chloride at a concentration of 9 mg/ml.
  • FIGS. 4 and 5 show the time course of particle size and Z-potential of a formulation obtained by reconstitution of a freeze dried mixture of paclitaxel, sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid and sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid in w/w/w ratio 1:0.75:0.75 in an aqueous solution of sodium chloride (9 mg/ml), calcium chloride (2 mmol/l) and magnesium chloride (1 mmol/l).
  • FIGS. 6 and 7 show the time course of particle size and Z-potential of a formulation obtained by reconstitution of a freeze dried mixture of docetaxel and sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid in w/w ratio 1:2 in an aqueous solution of sodium chloride (9 mg/ml) and calcium chloride (3 mmol/l)
  • FIG. 10 shows the dependence of the particle size on the w/w ratio of sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid to Ciclosporin A at different Ciclosporin A concentrations in an aqueous solution of sodium chloride at a concentration of 9 mg/ml.
  • the term “about” modifying the quantity of an ingredient in the drug delivery systems or compositions of the invention or employed in the methods of the invention refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the drug delivery systems or compositions or carry out the methods; and the like.
  • the term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term “about”, the claims include equivalents to the quantities.
  • drug delivery system refers to a formulation or device that delivers therapeutic agent(s) to desired body location(s) and/or provides timely release of therapeutic agent(s).
  • particle size refers to the Z-average diameter as measured by dynamic light scattering with the use of red laser with a wavelength of 633 nm.
  • an effective average particle size of less than about 100 nm it is meant that at least 90% of the particles have a size of less than about 100 nm when measured by the above-noted technique.
  • Nanoparticle refers to a microscopic particle whose size is measured in nanometers. Nanoparticles of the invention typically range from about 1 to about 999 nm in diameter, and can include an entrapped, encapsulated, or enclosed biologically active molecule.
  • solubility of a substance refers to the ability of that substance to be dissolved in a specified solvent at about room temperature, by which is meant from between about 15° C. to about 38° C.
  • amorphous is intended to indicate a solid structure that is either non-crystalline or consists of very small crystals having a particle size of about 10 nm or less.
  • cytotoxic compound refers to a compound that has the ability of arresting the growth of, or killing, cells.
  • cytostatic compound refers to a compound that has the ability of bringing cells, although not necessarily lysed or killed, into a permanent non-proliferative state.
  • immunosuppressant refers to a compound that has the ability of inhibiting the activity of the immune system, in particular for preventing rejection of a transplant organ and in disorders where the body's immune system attacks its own tissues
  • derivative refers to a compound formed from the original structure either directly, by chemical reaction of the original structure, or by a “modification” which is a partial substitution of the original structure, or by design and de novo synthesis.
  • Derivatives may be synthetic, or may be metabolic products of a cell or an in vitro enzymatic reaction.
  • the substance particles in the inventive drug delivery system have an effective average particle size of less than about 50 nm.
  • the substance particles in the inventive drug delivery system have an effective average particle size in the range of about 5-50 nm.
  • the substance particles in the inventive drug delivery system have an effective average particle size in the range of about 8-30 nm.
  • the weight-to-weight ratio of the sodium salt of methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to the pharmaceutically active substance is in the range from about 1:1 to about to 10:1.
  • the pharmaceutically active substance is a cytotoxic or a cytostatic compound; in one aspect of this embodiment the cytotoxic or cytostatic compound is bischloronitrosourea (Carmustine); in another aspect of this embodiment the cytotoxic or cytostatic compound is etoposide; in yet another aspect of this embodiment the cytotoxic or cytostatic compound is a taxane, and in a more specific aspect the taxane is chosen among paclitaxel, docetaxel, and derivatives thereof. In another specific aspect of said embodiment the invention relates to such a drug delivery system for use in treatment of cancer.
  • the pharmaceutically active substance is an immunosuppressant; in one aspect of this embodiment the immunosuppressant is chosen among ciclosporin, sirolimus, tacrolimus and derivatives thereof. In another aspect of said embodiment the invention relates to such a drug delivery system for use in post-allogeneic organ transplant.
  • the pharmaceutically active substance is a cytotoxic or a cytostatic compound; in one aspect of this embodiment the cytotoxic or cytostatic compound is bischloronitrosourea (Carmustine); in another aspect of this embodiment the cytotoxic or cytostatic compound is etoposide; in yet another aspect of this embodiment the compound is a taxane, which may be chosen among paclitaxel, docetaxel, and derivatives thereof; in another aspect of this embodiment of the present invention the pharmaceutically active substance is an immunosuppressant; in one aspect of this embodiment the immunosuppressant is chosen among ciclosporin, sirolimus, tacrolimus and derivatives thereof.
  • the pharmaceutical composition may be provided in the form of an aqueous solution, a gel, a cream, an ointment, a tablet, a capsule, or a softgel.
  • a further embodiment of the invention relates to the use of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, in the preparation of such a drug delivery system.
  • Yet another embodiment of the invention relates to a method for the preparation of a drug delivery system comprising nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, and at least one pharmaceutically active substance having a solubility per se in water of less than about 100 ⁇ g/ml, wherein said substance is provided in the form of essentially amorphous particles with an effective average particle size of less than about 100 nm; the size of said nanoparticles is controlled to have an effective average particle size of less than about 100 nm by adjusting the weight-to-weight ratio of said sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to said substance to be in the range from about 0.5
  • a yet further embodiment of the invention relates to a method for controlling the particle size and/or particle shape and/or particle size distribution of nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, and at least one pharmaceutically active substance having a solubility per se in water of less than about 100 ⁇ g/ml in a process for the preparation of a drug delivery system, wherein said substance is provided in the form of essentially amorphous particles with an effective average particle size of less than about 100 nm; the particle size and/or particle shape and/or particle size distribution of said nanoparticles is controlled by adjusting the weight-to-weight ratio of said sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid
  • Yet another embodiment of the invention relates to a method for controlling the particle size of nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, and at least one pharmaceutically active substance having a solubility per se in water of less than about 100 ⁇ g/ml in a process for the preparation of a drug delivery system, wherein said substance is provided in the form of essentially amorphous particles with an effective average particle size of less than about 100 nm; said essentially amorphous particles are submitted into and/or produced in an aqueous solution containing at least one ionized salt, said aqueous solution having an ionic strength I; and the particle size of the nanoparticles is increased by increasing I or decreased by decreasing I.
  • the pharmaceutically active substance is a taxane and said at least one ionized salt is sodium chloride.
  • said at least one ionized salt is sodium chloride.
  • the ionized salt comprises polyvalent cations, such as, for instance, double valenced cations.
  • polyvalent cations such as, for instance, double valenced cations.
  • Such cations do not only increase the ionic strength of the solvent in general, thereby increasing the particle size, but also stabilize the particles formed.
  • taxane-containing particles having a size within the range of about 10-100 nm significantly improves the therapeutic efficacy of these anti-cancer compounds by extension a blood circulation of the drugs, lowering their reticulo-endothelial clearance and selective penetration of defective vasculature.
  • taxanes in the form of such nanoparticles in vivo i.e. slow drug release and increased permeability of tumour vasculature
  • the activity of taxane formulations containing such nanoparticles is more expressed in vitro in different solid tumour cell lines.
  • cytotoxicity of these formulations dramatically depends on the particle size.
  • Another embodiment of the invention relates to a method for increasing the drug loading capacity of nanoparticles formed of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, and at least one pharmaceutically active substance having a solubility per se in water of less than about 100 ⁇ g/ml in a process for the preparation of a drug delivery system by providing said substance in the form of essentially amorphous particles with an effective average particle size of less than about 100 nm; and adjusting the weight-to-weight ratio of said sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, to said substance to be in the range from about 0.5:1 to about 20:1.
  • the pharmaceutically active substance may be provided in the form of essentially amorphous particles with an effective average particle size of less than about 100 nm by way of a method comprising the steps of: dissolving said substance in a suitable organic solvent to provide an organic solution of said substance; adding about 0.01-3 molar equivalents of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, to said organic solution; and evaporating said organic solvent from said organic solution to provide a residue which comprises the pharmaceutically active substance in the form of essentially amorphous particles.
  • the proposed method is based on the ability of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, as well as a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid to prevent crystallization of pharmaceutically active substance such as, for instance, taxanes.
  • the sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof co-crystallize with the pharmaceutically active substance, forming a film.
  • Water added to this film dissolves the sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, and provides the pharmaceutically active substance in a highly amorphous form with tremendously increased surface area.
  • the essentially amorphous particles of the pharmaceutically active substance can be provided in dry form by way of, for instance, evaporation, and then later on be dissolved in an aqueous solution comprising about 0.01-50 molar equivalents of said sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof.
  • said active substance particles may be dissolved in such a solution comprising about 0.1-5 molar equivalents of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof.
  • the essentially amorphous particles are possible to dissolve in a solution of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or combination thereof, within a couple of minutes.
  • a solution of the pharmaceutically active substance in an organic solvent is added to an aqueous solution of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, whereafter the organic solvent is evaporated, leaving an aqueous solution comprising the pharmaceutically active substance in an amorphous form.
  • This method can be optimized and simplified by arranging influx of organic solution of the pharmaceutically active substance into an evaporation flask containing an aqueous solution of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, simultaneously with evaporation.
  • the flow-rate of the organic solution, the internal pressure in the evaporation system as well as the evaporation temperature may be chosen in such a way that concentration of organic solution does not exceed 15%.
  • the organic solvent used in the process for providing the pharmaceutically active substance in the form of essentially amorphous particles may be an alcohol such as, for instance, methanol or ethanol.
  • methanol which has lower boiling point instead of ethanol simplifies the evaporation of the alcohol-water mixtures.
  • the organic solutions of the essentially amorphous particles of pharmaceutically active substance may, for instance, be freeze-dried to remove the organic solvent, leaving the essentially amorphous particles of pharmaceutically active substance in a convenient powder form for storage and preparation of new formulations.
  • the water soluble taxane formulations obtained with the use of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, are stable for several hours in the broad interval of conditions of formation of these formulations.
  • the present invention makes it possible to provide aqueous solutions of taxanes with otherwise poor water solubility, like paclitaxel and docetaxel, for infusion without any use of non-ionic surfactants. This significantly reduces hypersensitivity reaction against the infusion solutions, shortens the infusion time, and obviates the need of premedication of patients against such hypersensitivity.
  • Formulations of active pharmaceutical ingredients with a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid, a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid, or a combination thereof, were prepared by reconstitution of either freshly evaporated or freeze dried residues of an active ingredient with the retinoyl cysteic acid derivatives by a specified solution for reconstitution.
  • Paclitaxel, Ciclosporine A and all-trans-retinoic acid were purchased from Sigma-Aldrich Sweden AB.
  • Docetaxel was purchased from ScinoPharm Taiwan, Ltd.
  • Ixabepilone was purchased from Chemtronica KB, Sweden.
  • Fenretinide was synthesized according to a standard procedure (Cancer Research, 39, 1339-1346, April 1979).
  • Taxol, Taxotere and Abraxane were purchased from pharmacy stores and reconstituted according to manufacturers prescribing information.
  • Particle size of formulations was measured by dynamic light scattering method with the use of a red laser (633 nm).
  • Zeta(Z)-potential was measured by electrophoretic light scattering method.
  • Nano-ZS (Malvern Instruments Ltd.) was used for determination both particle size and zeta-potential. Average values of three independent measurements were calculated for plotting of particle size and zeta-potential behaviour. Y-error bars are composed by +/ ⁇ standard deviation of the measurements.
  • MDA-MB-231 Human Breast Adenocarcinoma Cell Line MDA-MB-231 (ATCC-HTB-26, Lot 3576799), Human Ovary Adenocarcinoma Cell Line SKOV-3 (ATCC-HTB-77, Lot 3038337) and Human Lung Non-Small Cancer Cell Line A549 (ATCC-CCL-185, Lot 3244171).
  • MDA-MB-231 cells were propagated in MEM culture medium with 2 mM L-glutamine, 10% fetal bovine serum (FBS) and antibiotics.
  • FBS fetal bovine serum
  • SKOV-3 cells were cultured in McCoy's 5A culture medium, supplemented with 1,5 mM L-glutamine, 10% FBS and antibiotics. All media and supplements were purchased from Sigma-Aldrich Co. (St. Louis, Mi., USA). Cell propagation of all lines was carried out in BD FalconTM 25 or 75 cm 2 cultivation flasks (Becton Dickinson Labware). A549 cells were cultured in Ham's F-12 culture medium with 1 mM L-glutamine, 10% FBS and antibiotics. Cell propagation of all lines was carried out in BD FalconTM 25 or 75 cm 2 cultivation flasks.
  • Drug cytotoxicity testing was carried out using BD FalconTM 96-well cultivation plates for adherent cells (Becton Dickinson Labware). These plates were seeded by cells at 8 ⁇ 10 3 cells/well for MDA-MB-231, at 10 ⁇ 10 3 cells/well for SKOV-3 or at 6 ⁇ 10 3 cells/well for A549 in a volume of 200 ⁇ l/well. Both flasks and cultivation plates were incubated for cell growth at 37° C. in a humidified atmosphere of 95% air and 5% CO 2 .
  • the cell cultures in the cultivation plates were allowed to adhere for 24 hour of incubation. On day 1 after cell seeding 4 ⁇ L solutions of the formulations to be tested with different concentrations in appropriate solvents were added to wells with cultures (dose—response experiments). In the control cultures 4 ⁇ L of the solvents were added as solvent control. The cells were incubated within 2-4 consecutive days. At the end of the incubation period adherent cells were detached by trypsinization and the number of viable cells was counted using trypan blue exclusion test and a hemocytometer. All experiment were performed at least three times and data were derived from an average of three determinations each in four replicates. The results were expressed as mean cell number ⁇ SE and the differences between control and test series evaluated by means of Student's t-test. The drug cytotoxicity was evaluated based on the extent of cell growth inhibition. The cell growth inhibition by the tested drugs was calculated as follows:
  • control series 4 ⁇ L of different solvents used for drug testing were added to cultures as negative solvent controls. The differences between these control series were insignificant; therefore an average of negative controls was applied for calculations.
  • the mean IC 50 ⁇ SE was calculated on the bases of at least three separate experiments.
  • Enhancement factors were calculated by dividing of IC 50 of the control comparison drug with IC 50 of the inventive formulation.
  • the ionic strength of a solution is a function of the concentration of all ions present in a solution.
  • c B is the concentration of ion B
  • z B is the charge number of that ion, and the sum is taken over all ions in the solution.
  • the total volume of added ethanol solution was 30 ml.
  • the aqueous solution remaining after the evaporation of ethanol was transferred from the flask into a 250 ml measuring cylinder.
  • the flask was rinsed three times with 5 ml water and the rinsing solutions were poured into the cylinder. Water was added to the combined solutions to achieve a total volume 150 ml. After filtration through a 0.2 ⁇ m filter the formulation was freeze dried.
  • the docetaxel concentration in the obtained formulation was 1 mg/ml.
  • a 1000 ml round bottom flask containing 150 ml of an aqueous solution of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid (3 mg/ml) and a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid (3 mg/ml) was attached to a rotary evaporator equipped with an inlet pipe for feeding of alcohol solutions of taxanes in such a way that the inlet pipe did not come in touch with the aqueous solution.
  • the evaporation started with a bath temperature of 45° C. and a rotation speed of 100 rpm.
  • the solutions were prepared by reconstitution of freeze-dried powder contained docetaxel and a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid in the w/w ratio 1:1.
  • Aqueous solutions of a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid (5 ml, 15 mg/ml) and calcium chloride (3 ml, 30 mg/ml) were mixed in a 10 ml test tube. During the mixing a fine precipitation emerged. The precipitate was separated by centrifugation of the test tube at 3000 rpm for 10 min. The supernatant was removed and the precipitate was shaken with 8 ml of water followed by a new centrifugation. After three additional washing procedures as described above the supernatant was filtered through a 0.2 ⁇ m filter in order to remove possible large aggregates of the product.
  • the solubility of the calcium salt of the methyl ester of N-all-trans-retinoyl cysteic acid corresponded to its concentration in the filtered solution and was equal to 0.2 mg/ml as measured by the UV method described above.
  • the reaction is illustrated by the below general scheme involving chlorides of any polyvalent metal ions, not only calcium ions.
  • Solutions were prepared by reconstitution of freeze-dried powder containing paclitaxel, a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid and a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid in the w/w/w ratio 1:1:1.
  • Solvents for the reconstitution were prepared by dissolving of appropriate amounts of calcium chloride dihydrate in an aqueous solution of sodium chloride with a concentration 9 mg/ml.
  • Paclitaxel Paclitaxel concentration concentration concentration concentration 0.5 mg/ml 1 mg/ml 2 mg/ml Average Average Average Concentration of particle St. particle St. particle St. CaCl 2 , mmol/l size, nm dev. size, nm dev. size, nm dev. 0 12.7 0.4 16.3 1.1 22.1 0.2 2 23.8 1.7 24.6 0.5 27.3 0.2 4 27.4 0.2 30.1 0.4 32.0 0.1 6 51.0 0.6 55.2 5.1 58.6 1.6
  • Paclitaxel Paclitaxel concentration concentration concentration concentration 0.5 mg/ml 1 mg/ml 2 mg/ml Average Average Average Time after re- particle St. particle St. particle St. constitution size, nm dev. size, nm dev. size, nm dev. 0 22.1 0.5 23.5 0.5 25.6 0.8 1 22.7 0.7 24.1 0.8 26.3 0.7 2 23.1 0.5 24.3 0.4 26.2 0.5 4 23 0.4 24.4 0.3 26.6 0.2 8 23.4 0.7 24.0 0.6 27.0 0.4
  • Paclitaxel Paclitaxel concentration concentration concentration concentration 0.5 mg/ml 1 mg/ml 2 mg/ml Zeta- Zeta- Zeta- Time after potential, St. potential, St. potential, St. reconstitution mV dev. mV dev. mV dev. 0 ⁇ 24.5 1.3 ⁇ 28.7 1.2 ⁇ 29.9 1.1 1 ⁇ 26.3 1.8 ⁇ 30.1 1.0 ⁇ 32.7 0.8 2 ⁇ 25.2 0.4 ⁇ 30.4 1.0 ⁇ 30.6 0.5 4 ⁇ 27.0 0.5 ⁇ 29.6 0.6 ⁇ 31.2 0.3 8 ⁇ 27.1 0.4 ⁇ 30.4 0.3 ⁇ 32.4 0.6
  • FIGS. 4 and 5 show that there are no any significant changes in the values of the particle size as well as Zeta-potential during storage of the formulation for 8 hours.
  • Docetaxel concentration concentration concentration concentration 0.5 mg/ml 1 mg/ml 2 mg/ml Average Average Average Time after re- particle St. particle St. particle St. constitution size, nm dev. size, nm dev. size, nm dev. 0 11.9 0.3 12.6 0.2 13.1 0.4 1 12.3 0.3 13.2 0.4 13.4 0.2 2 12.4 0.2 13.0 0.2 13.7 0.4 4 12.2 0.4 12.9 0.1 13.4 0.2 8 12.5 0.3 13.2 0.2 13.8 0.2
  • Paclitaxel Paclitaxel concentration concentration concentration concentration 0.5 mg/ml 1 mg/ml 2 mg/ml Zeta- Zeta- Zeta- Time after potential, St. potential, St. potential, St. reconstitution mV dev. mV dev. mV dev. 0 ⁇ 22.2 2.1 ⁇ 22.6 1.3 ⁇ 22.8 0.6 1 ⁇ 23.4 0.9 ⁇ 22.4 1.2 ⁇ 24.1 0.8 2 ⁇ 22.7 0.4 ⁇ 23.7 0.9 ⁇ 23.3 0.4 4 ⁇ 21.9 0.3 ⁇ 23.1 0.8 ⁇ 23.1 0.2 8 ⁇ 21.7 0.6 ⁇ 23.4 0.6 ⁇ 23.5 0.5
  • FIGS. 6 and 7 show that there are no any significant changes in the values of the particle size as well as Zeta-potential during storage of the formulation for 8 hours.
  • the Ciclosporin A film was completely dissolved by gentle shaking of the vial for 10 min. The obtained solution was clear and transparent. It contained dissolved Ciclosporin A in a concentration of 1 mg/ml. Filtration the solution through 0.2 ⁇ m filter did not result in any reduction of the Ciclosporin A concentration.
  • Ciclosporin A Ciclosporin A methyl ester concentration concentration concentration concentration concentration of N-all-trans- 0.5 mg/ml 1 mg/ml 2 mg/ml 4 mg/ml retinoyl Average Average Average Average cysteic acid/ particle particle particle particle Ciclosporin A size, nm St. dev. size, nm St. dev. size, nm St. dev. size, nm St. dev. size, nm St. dev.
  • taxane formulations according to the invention possess more expressed cytotoxic activity against different malignant cell culture lines like breast adenocarcinoma, ovary adenocarcinoma and lung non-small cell cancer.
  • Freeze dried powder consisted of docetaxel, a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid and a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid was dissolved in either 70% ethanol or sodium chloride solution (9 mg/ml) containing an appropriate amount of calcium chloride. Samples of the solutions obtained were taken and used for measurement of average particle size.
  • Table 9 and FIG. 8 show that the formulation contained 2 mmol/l of calcium is the most active. Then with increase and decrease of calcium concentration the cytotoxicity of the formulations is reduced.
  • Freeze dried powder consisting of paclitaxel, a sodium salt of the methyl ester of N-all-trans-retinoyl cysteic acid and a sodium salt of the methyl ester of N-13-cis-retinoyl cysteic acid was dissolved in either 70% ethanol or sodium chloride solution (9 mg/ml) containing an appropriate amount of calcium chloride. Samples of the solutions obtained were taken and used for measurement of average particle size.
  • Table 10 and FIG. 9 show that the formulation contained 2 mmol/l of calcium is the most active. Then with increase and decrease of calcium concentration the cytotoxicity of the formulations is reduced.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Paclitaxel was used in a methanol solution.
  • TAXOL® and ABRAXANE® samples were prepared according to instructions from the manufacturers by dilution of a commercially available TAXOL® concentrate (6 mg/ml) in sodium chloride (9 mg/ml) solution and by reconstitution of freeze dried albumin-bound paclitaxel with sodium chloride (9 mg/ml) solution to a paclitaxel concentration of 5 mg/ml. All samples were used within one hour after preparation. Enhancement effects were calculated versus paclitaxel methanol solution. The results are set forth in Table 11 below.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Docetaxel was used in a methanol solution.
  • TAXOTERE® sample was prepared according to instructions from the manufacturer by dilution of a commercially available concentrate (40 mg/ml) firstly with ethanol solution to concentration 10 mg/ml followed by further dilution in sodium chloride (9 mg/ml) solution. All samples were used within one hour after preparation. Enhancement effects were calculated versus docetaxel methanol solution. The results are set forth in Table 12 below.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Paclitaxel was used in a methanol solution.
  • TAXOL® and ABRAXANE® samples were prepared according to instructions from the manufacturers by dilution of a commercially available TAXOL® concentrate (6 mg/ml) in sodium chloride (9 mg/ml) solution and by reconstitution of freeze dried albumin-bound paclitaxel with sodium chloride (9 mg/ml) solution to a paclitaxel concentration of 5 mg/ml. All samples were used within one hour after preparation. Enhancement effects were calculated versus paclitaxel methanol solution. The results are set forth in Table 13 below.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Docetaxel was used in a methanol solution.
  • TAXOTERE® sample was prepared according to instructions from the manufacturer by dilution of a commercially available concentrate (40 mg/ml) firstly with ethanol solution to concentration 10 mg/ml followed by further dilution in sodium chloride (9 mg/ml) solution. All samples were used within one hour after preparation. Enhancement effects were calculated versus docetaxel methanol solution. The results are set forth in Table 14 below.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Paclitaxel was used in a methanol solution.
  • TAXOL® and ABRAXANE® samples were prepared according to instructions from the manufacturers by dilution of a commercially available TAXOL® concentrate (6 mg/ml) in sodium chloride (9 mg/ml) solution and by a reconstitution of freeze dried albumin-bound paclitaxel with sodium chloride (9 mg/ml) solution to a paclitaxel concentration of 5 mg/ml. All samples were used within one hour after preparation. Enhancement effects were calculated versus paclitaxel methanol solution. The results are set forth in Table 15 below.
  • the title formulation was prepared by dissolving freeze dried powder in an aqueous solution containing sodium chloride (6 mg/ml), potassium chloride (0.3 mg/ml), calcium chloride hexahydrate (0.4 mg/ml), sodium lactate (3.1 mg/ml). Docetaxel was used in a methanol solution.
  • TAXOTERE® sample was prepared according to instructions from the manufacturer by dilution of a commercially available concentrate (40 mg/ml) firstly with ethanol solution to concentration 10 mg/ml followed by further dilution in sodium chloride (9 mg/ml) solution. All samples were used within one hour after preparation. Enhancement effects were calculated versus docetaxel methanol solution. The results are set forth in Table 16 below.
  • the tested formulation was prepared by reconstitution in saline of freeze dried mixture of Paclitaxel-Sodium Salt of the Methyl Ester of N-all-trans-retinoyl Cysteic Acid-Sodium Salt of the Methyl Ester of N-13-cis-retinoyl Cysteic Acid (w/w/w 1:0.75:075).
  • 80 Wistar rats BRLHan:Wist@Mol (GALAS)
  • 40 males and 40 females were divided into 4 groups, each of 10 males and 10 females. Tested formulations were administered by intravenous injection once weekly over 5 weeks.
  • Group 1 received saline and acted as controls
  • Group 2 received 5 mg/kg of formulation of paclitaxel with polyoxyethylated castor oil (Taxol®)
  • Group 3 received 5 mg/kg of the title formulation
  • Group 4 received 10 mg/kg of the title formulation.
  • the study was designed so that Group 2 would receive 10 mg/kg Taxol® as a direct comparison with Group 4, however, due to mortality, this dosage was reduced to 5 mg/kg such that a direct comparison with Group 3 was more appropriate.
  • red blood cell parameters Hb, RBC and HT
  • values for the red cell indices MCV in males of Group 2 were elevated.
  • Mean values for white blood cells, particularly neutrophils, lymphocytes, eosinophils and in the males, monocytes in treated animals were lower than for controls.
  • Mean serum bilirubin values for males in Group 4 and females in Group 2 and 4 were higher than for the controls. Bilirubin for females in Group 2 (Taxol®) was significantly higher than for the females in Group 3. Liver weight in males of Groups 2 and 4 was significantly lower than for the controls.
  • Thymus weight for males and females in Group 4 and for the males in Group 2 was significantly lower than for the control. Relatively high incidence of minimal to slight lymphoid atrophy was recorded in the spleen, the mesenteric- and mandibular lymph node of Group 4. Low incidence of minimal to slight lymphoid atrophy was recorded in the spleen of Groups 2 and 3. The incidence lymphoid atrophy of the spleen was slightly higher in the Group 2 males. Low incidence of minimal to slight lymphoid atrophy was rerecorded in the mesenteric- and mandibular lymph nodes of Group 2. Minimal to slight increased cortical lymphocytolysis was recorded in all males of Group 2.
  • nano-particle formulation “Paclitaxel-Sodium Salt of the Methyl Ester of N-all-trans-retinoyl Cysteic Acid-Sodium Salt of the Methyl Ester of N-13-cis-retinoyl Cysteic Acid (w/w/w 1:0.75:075)” has a lower toxicity as compared to identical concentrations of conventional formulation of paclitaxel with polyoxyethylated castor oil.
  • nano-particle formulation “Paclitaxel-Sodium Salt of the Methyl Ester of N-all-trans-retinoyl Cysteic Acid-Sodium Salt of the Methyl Ester of N-13-cis-retinoyl Cysteic Acid” as compared to conventional formulation of paclitaxel with polyoxyethylated castor oil (Taxol®).
  • Taxol® polyoxyethylated castor oil
  • Paclitaxel-Sodium Salt of the Methyl Ester of N-all-trans-retinoyl Cysteic Acid-Sodium Paclitaxel- Salt of the Methyl Ester of polyoxyethylated N-13-cis-retinoyl Cysteic Acid castor oil Dose level/m 2 250 175 Premedication with None Yes steroids, antiemetics and antihistamines Anaphylaxis and None (without premedication) 5% (All patients severe received hypersensitivity premedication) reactions Infusion time 1 hour 3 hours

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/809,252 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances Active 2030-05-08 US8999382B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/899,848 USRE49741E1 (en) 2007-12-19 2020-06-12 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US17/177,550 USRE49742E1 (en) 2007-12-19 2021-02-17 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
SEPCT/SE2007/001127 2007-12-19
WOPCT/SE2007/001127 2007-12-19
PCT/SE2008/051515 WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2008/051515 A-371-Of-International WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/633,177 Continuation US9993438B2 (en) 2007-12-19 2015-02-27 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (2)

Publication Number Publication Date
US20110014281A1 US20110014281A1 (en) 2011-01-20
US8999382B2 true US8999382B2 (en) 2015-04-07

Family

ID=40795732

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/809,252 Active 2030-05-08 US8999382B2 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US14/633,177 Ceased US9993438B2 (en) 2007-12-19 2015-02-27 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US16/899,848 Active USRE49741E1 (en) 2007-12-19 2020-06-12 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US17/177,550 Active USRE49742E1 (en) 2007-12-19 2021-02-17 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/633,177 Ceased US9993438B2 (en) 2007-12-19 2015-02-27 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US16/899,848 Active USRE49741E1 (en) 2007-12-19 2020-06-12 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US17/177,550 Active USRE49742E1 (en) 2007-12-19 2021-02-17 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Country Status (27)

Country Link
US (4) US8999382B2 (ko)
EP (1) EP2231189B1 (ko)
JP (1) JP5466172B2 (ko)
KR (1) KR101572703B1 (ko)
CN (1) CN101951956B (ko)
AU (1) AU2008339099B2 (ko)
BR (1) BRPI0821740B1 (ko)
CA (1) CA2709266C (ko)
CY (2) CY1119805T1 (ko)
DK (1) DK2231189T3 (ko)
EA (1) EA015247B1 (ko)
ES (1) ES2650242T3 (ko)
FR (1) FR19C1030I1 (ko)
HR (1) HRP20171796T1 (ko)
HU (1) HUE034684T2 (ko)
LT (2) LT2231189T (ko)
LU (1) LUC00117I2 (ko)
MX (1) MX2010006914A (ko)
MY (2) MY157187A (ko)
NL (1) NL300987I9 (ko)
NO (2) NO2231189T3 (ko)
NZ (1) NZ586859A (ko)
PL (1) PL2231189T3 (ko)
PT (1) PT2231189T (ko)
SI (1) SI2231189T1 (ko)
WO (2) WO2009078754A1 (ko)
ZA (1) ZA201004685B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993438B2 (en) * 2007-12-19 2018-06-12 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
MX2011011134A (es) * 2009-04-21 2012-01-31 Selecta Biosciences Inc Agentes inmunonanoterapeuticos que proporcionan una respuesta sesgada hacia th1.
MX2012013713A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Composiciones de nanovehiculos con adyuvante no acoplado.
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) * 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
WO2001017546A1 (en) 1999-09-09 2001-03-15 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2002092600A1 (en) 2001-05-15 2002-11-21 Ardenia Investments Ltd. Retinol derivatives potentiation of active substances by micellar preparation
US20040048923A1 (en) 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
WO2006017246A2 (en) 2004-07-12 2006-02-16 Sd Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
EP1666031A1 (en) 2003-09-04 2006-06-07 NanoCarrier Co., Ltd. Composition containing nanoparticles containing water-soluble basic drug encapsulated therein
WO2006106519A2 (en) 2005-04-07 2006-10-12 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
WO2007001356A2 (en) 2004-09-10 2007-01-04 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
US20070082838A1 (en) 2005-08-31 2007-04-12 Abraxis Bioscience, Inc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078803A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078804A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
CN100360502C (zh) * 2002-07-23 2008-01-09 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
WO2001017546A1 (en) 1999-09-09 2001-03-15 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2002092600A1 (en) 2001-05-15 2002-11-21 Ardenia Investments Ltd. Retinol derivatives potentiation of active substances by micellar preparation
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20040048923A1 (en) 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds
EP1666031A1 (en) 2003-09-04 2006-06-07 NanoCarrier Co., Ltd. Composition containing nanoparticles containing water-soluble basic drug encapsulated therein
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
WO2006017246A2 (en) 2004-07-12 2006-02-16 Sd Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2007001356A2 (en) 2004-09-10 2007-01-04 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
WO2006106519A2 (en) 2005-04-07 2006-10-12 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20070082838A1 (en) 2005-08-31 2007-04-12 Abraxis Bioscience, Inc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009078803A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078804A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
D. V. Arsenov et al., "Synthesis of N-(all-transretinoyl)doxorubicin and study of the antitumor activity of its complex with blood serum proteins", Pharmaceutical Chemistry Journal, 2001, vol. 35, No. 4, pp. 186-189 (copy to be provided).
D. V. Arsenov et al., "Synthesis of N-(all-transretinoyl)doxorubicin and study of the antitumor activity of its complex with blood serum proteins", Pharmaceutical Chemistry Journal, 2001, vol. 35, No. 4, pp. 186-189 (Previously identified in Information Disclosure Statement filed on Jun. 18, 2010, copy now provided).
International Preliminary Report on Patentability for corresponding International Application No. PCT/SE2008/051515 mailed Oct. 19, 2009.
International Preliminary Report on Patentability for corresponding International Application No. PCT/SE2008/051516 mailed Mar. 25, 2010.
International Preliminary Report on Patentability for corresponding International Application No. PCT/SE2008/051517 mailed Mar. 25, 2010.
International Search Report for corresponding International Application No. PCT/SE2008/051515 mailed Mar. 20, 2009.
International Search Report for corresponding International Application No. PCT/SE2008/051516 mailed Mar. 20, 2009.
International Search Report for corresponding International Application No. PCT/SE2008/051517 mailed Mar. 20, 2009.
Mahesh Chavanpatil et al., "Polymer-Surfactant Nanoparticles for Sustained Release of Water-Soluble Drugs", Journal of Pharmaceutical Sciences, Dec. 2007, vol. 96, No. 12 pp. 3379-3389 (copy to be provided).
Mahesh Chavanpatil et al., "Polymer-Surfactant Nanoparticles for Sustained Release of Water-Soluble Drugs", Journal of Pharmaceutical Sciences, Dec. 2007, vol. 96, No. 12 pp. 3379-3389 (Previously identified in Information Disclosure Statement filed on Jun. 18, 2010, copy now provided).
NPL website: Aerosols & Particulate Matter (www.mfg.mtu.edu/cyberman/environment/air/pmintro.html); downloaded Feb. 23, 2014. *
Office Action issued Jun. 25, 2013 in the copending Japanese Patent Application No. 2010-539386.
PCT Communication in Cases for Which No Other Form Is Suitable-Corrected International Search Report and Written Opinion for corresponding International Application No. PCT/SE2008/051517 mailed Apr. 1, 2009.
Saadia Hassan et al., "Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo", Cancer Chemother Pharmacol, 2005, vol. 55, pp. 47-54 (copy to be provided).
Saadia Hassan et al., "Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo", Cancer Chemother Pharmacol, 2005, vol. 55, pp. 47-54 (Previously identified in Information Disclosure Statement filed on Jun. 18, 2010, copy now provided).
Torchilin, "Micellar Nanocarriers: Pharmaceutical Perspectives", Pharmaceutical Research, vol. 24, No. 1, Jan. 2007, pp. 1-16.
Written Opinion for corresponding International Application No. PCT/SE2008/051515 mailed Mar. 20, 2009.
Written Opinion for corresponding International Application No. PCT/SE2008/051516 mailed Mar. 20, 2009.
Written Opinion for corresponding International Application No. PCT/SE2008/051517 mailed Mar. 20, 2009.
Written Opinion of the International Preliminary Examining Authority for corresponding International Application No. PCT/SE2008/051515 mailed Nov. 20, 2009.
Written Opinion of the International Preliminary Examining Authority for corresponding International Application No. PCT/SE2008/051516 mailed Nov. 20, 2009.
Written Opinion of the International Preliminary Examining Authority for corresponding International Application No. PCT/SE2008/051517 mailed Nov. 20, 2009.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993438B2 (en) * 2007-12-19 2018-06-12 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
USRE49742E1 (en) * 2007-12-19 2023-12-05 Vivesto Ab Drug delivery system for administration of poorly water soluble pharmaceutically active substances
USRE49741E1 (en) * 2007-12-19 2023-12-05 Vivesto Ab Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Also Published As

Publication number Publication date
KR20100094575A (ko) 2010-08-26
FR19C1030I1 (fr) 2019-06-21
WO2009078802A1 (en) 2009-06-25
EA200802350A3 (ru) 2009-10-30
ZA201004685B (en) 2011-03-30
SI2231189T1 (en) 2018-03-30
LUC00117I2 (ko) 2024-05-22
NZ586859A (en) 2012-06-29
CA2709266C (en) 2017-09-26
LT2231189T (lt) 2017-12-27
EP2231189A4 (en) 2013-10-09
US20110014281A1 (en) 2011-01-20
PT2231189T (pt) 2017-12-12
CN101951956B (zh) 2012-10-17
US20150164819A1 (en) 2015-06-18
LTPA2019508I1 (lt) 2019-05-10
HRP20171796T1 (hr) 2018-01-26
BRPI0821740B1 (pt) 2021-05-18
DK2231189T3 (en) 2017-12-11
EP2231189B1 (en) 2017-09-06
MY157186A (en) 2016-05-13
JP2011507838A (ja) 2011-03-10
KR101572703B1 (ko) 2015-11-27
BRPI0821740A2 (pt) 2020-02-27
NO2231189T3 (ko) 2018-02-03
CN101951956A (zh) 2011-01-19
ES2650242T3 (es) 2018-01-17
PL2231189T3 (pl) 2018-03-30
AU2008339099A1 (en) 2009-06-25
USRE49742E1 (en) 2023-12-05
WO2009078754A1 (en) 2009-06-25
EA200802350A2 (ru) 2009-06-30
USRE49741E1 (en) 2023-12-05
CA2709266A1 (en) 2009-06-25
CY2019021I1 (el) 2019-11-27
HUE034684T2 (en) 2018-02-28
NO2019023I1 (no) 2019-05-08
NL300987I2 (ko) 2019-05-09
CY1119805T1 (el) 2018-06-27
NL300987I9 (nl) 2019-05-16
EA015247B1 (ru) 2011-06-30
EP2231189A1 (en) 2010-09-29
JP5466172B2 (ja) 2014-04-09
CY2019021I2 (el) 2019-11-27
AU2008339099B2 (en) 2015-08-13
US9993438B2 (en) 2018-06-12
MX2010006914A (es) 2010-11-10
MY157187A (en) 2016-05-13

Similar Documents

Publication Publication Date Title
USRE49742E1 (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
RU2451510C2 (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
US8728527B2 (en) Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
CN102056596B (zh) 纳米颗粒制剂及其用途
JP2020023564A (ja) 組成物及び薬物送達方法
KR20180098702A (ko) 약리학적 물질의 조성물 및 그 전달방법
CN101291658A (zh) 用于制备稳定性增加的水难溶性药物的组合物和方法
MX2010006907A (es) Sistema de suministro de farmaco para administrar una substancia farmaceuticamente activa soluble en agua, cationica y anfifilica.
CN112121028B (zh) 一种辛伐他汀固体纳米粒制剂及其制备方法
RU2522977C2 (ru) Композиции и способы доставки фармакологических агентов
CA3193020A1 (en) Stabilized solid nanoparticle formulations of cannabinoids and cannabinoid analogs with reduced ostwald ripening for oral, inhalation, nasal and parenteral drug delivery
UA96273C2 (uk) Композиція доцетакселу і цитрату для лікування раку

Legal Events

Date Code Title Description
AS Assignment

Owner name: ARDENIA INVESTMENTS, LTD., UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALEKSOV, JULIAN;LOKOT, IGOR;REEL/FRAME:025015/0643

Effective date: 20100701

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

AS Assignment

Owner name: OASMIA PHARMACEUTICAL AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARDENIA INVESTMENTS, LTD.;REEL/FRAME:050338/0853

Effective date: 20010907

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8